Self-Reported Sleep Duration and Quality and Cardiovascular Disease and Mortality: A Dose-Response Meta-Analysis

Chun Shing Kwok, MBBS, MSc, BSc; Evangelos Kontopantelis, PhD; George Kuligowski; Matthew Gray; Alan Muhyaldeen; Christopher P. Gale, MBBS, MSc, BSc, PhD; George M. Peat, PhD; Jacqueline Cleator, RGN, BA, MA, PhD; Carolyn Chew-Graham, MB, ChB, MD; Yoon Kong Loke, MD; Mamas Andreas Mamas, BM, BCh, MA, DPhil

Background—There is growing evidence that sleep duration and quality may be associated with cardiovascular harm and mortality.

Methods and Results—We conducted a systematic review, meta-analysis, and spline analysis of prospective cohort studies that evaluate the association between sleep duration and quality and cardiovascular outcomes. We searched MEDLINE and EMBASE for these studies and extracted data from identified studies. We utilized linear and nonlinear dose-response meta-analysis models and used DerSimonian–Laird random-effects meta-analysis models of risk ratios, with inverse variance weighting, and the I² statistic to quantify heterogeneity. Seventy-four studies including 3 340 684 participants with 242 240 deaths among 2 564 029 participants who reported death events were reviewed. Findings were broadly similar across both linear and nonlinear dose-response models in 30 studies with >1 000 000 participants, and we report results from the linear model. Self-reported duration of sleep >8 hours was associated with a moderate increased risk of all-cause mortality, with risk ratio, 1.14 (1.05–1.25) for 9 hours, risk ratio, 1.30 (1.19–1.42) for 10 hours, and risk ratio, 1.47 (1.33–1.64) for 11 hours. No significant difference was identified for periods of self-reported sleep <7 hours, whereas similar patterns were observed for stroke and cardiovascular disease mortality. Subjective poor sleep quality was associated with coronary heart disease (risk ratio, 1.44; 95% confidence interval, 1.09–1.90), but no difference in mortality and other outcomes.

Conclusions—Divergence from the recommended 7 to 8 hours of sleep is associated with a higher risk of mortality and cardiovascular events. Longer duration of sleep may be more associated with adverse outcomes compared with shorter sleep durations. (J Am Heart Assoc. 2018;7:e008552. DOI: 10.1161/JAHA.118.008552.)

Key Words: cardiac risk factors • coronary artery disease • meta-analysis • prevention

Cardiovascular disease (CVD) causes over 787 000 deaths in the United States.1 Whereas sleep duration is generally not considered a traditional risk factor for cardiovascular disease (CVD), growing evidence supports its association with cardiovascular risk (CVR) factors2–7 and disease,8–11 and quality of sleep appears to contribute to CVR.10,12 Yet, current guidelines for the risk reduction of CVD make limited recommendations about quality or duration of sleep.13,14 The National Sleep Foundation recommends 7 to 9 hours of sleep for people aged 26 to 64 years and 7 to 8 hours of sleep for people aged ≥65 years,14 and the Centers for Disease Control and Prevention has similar recommendations for adults.15 Whether adults sleep the recommended hours is influenced by cultural, social, psychological, behavioral, pathophysiological, and environmental influences.16,17 Sleep duration may be reduced...
because of irregular working and shift-work patterns and round-the-clock availability of commodities of modern society. However, guidelines make no specific reference with regard to sleeping beyond the recommended limit. Long sleep duration may be associated with obstructive sleep apnea, heart disease, and failing health or may represent a symptom of early “latent” disease preceding a formal diagnosis.

Although previous reviews have evaluated sleep duration and mortality and cardiovascular outcomes, these reviews have not quantified the CVR associated with each hour deviation below or above the recommended sleep duration. In addition, none of the previous reviews assessed the influence of sleep quality. Thus, we conducted a systematic review and meta-analysis of the impact of sleep duration and quality on CVD and mortality.

Methods

Data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

The full methods, including detailed eligibility criteria, search strategy, data selection, extraction, and analysis, are reported in Data S1. The article was prepared according the guidance of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) statement (Data S2).

Eligibility Criteria

We selected prospective cohort studies that reported on participants who quantified their duration of sleep or quality of sleep, and their association with subsequent CVD and mortality. The primary outcome was all-cause mortality, and secondary outcomes were CVD and mortality.

Search Strategy

We searched Medline and Embase using Ovid SP (from inception to the end of October 2015) using the search terms in Data S3.

Study Selection and Data Extraction

Two reviewers (C.S.K. and A.M.) checked all titles and abstracts for studies that could potentially meet the inclusion criteria. Data extraction and risk of bias assessment were performed independently by at least 2 reviewers (C.S.K., G.K., or M.G.). Publication bias was assessed using funnel plots.

Statistical Analysis

We used Stata software (version 14; StataCorpLP, College Station, TX) to perform regression analysis with random-effects dose-response meta-analysis models to estimate the association between hours of sleep and adverse outcomes, using 7 hours of sleep as the reference category. The linear model represents the primary analysis, and the cubic model was included as a supplemental analysis.

Conventional random-effects meta-analysis was performed as a secondary analysis using RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). We decided to use random-effects models because they are more conservative compared with fixed-effect models, in the presence of any heterogeneity. Statistical heterogeneity was assessed using the I² statistic. The details of the main and sensitivity analyses are described in Data S1. We also performed analysis of sleep quality (Data S4) in relation to mortality and cardiovascular outcomes.

Results

Description of Included Studies

A total of 74 studies met the inclusion criteria; the process of study selection is shown in Figure 1. Study design and participant characteristics are shown in Table 1. The included studies were dated 1970–2017, which represented 3 340 684 participants. Among studies that reported crude events, there were 242 240 all-cause deaths in 2 564 029 participants from 44 studies (9.4%), 5435 coronary heart disease (CHD) deaths in 741 695 participants from
7 studies (0.7%), 6380 stroke deaths in 374,728 participants from 5 studies (1.7%), 32,988 cardiovascular deaths in 759,939 participants from 14 studies (4.3%), 32,084 CHD events in 540,538 participants from 14 studies (5.9%), 14,946 stroke events in 525,620 participants from 11 studies (2.8%), and 4160 CVD events in 97,832 participants from 6 studies (4.3%). Data S5 shows the prevalence of CVD and CVR factor profiles for each cohort.

Quality Assessment of Included Studies

The quality assessment is shown in Data S6. Studies used questionnaires or direct questioning to ascertain information about sleep quality or sleep duration. Methods used to estimate outcomes included population registries, death certification, questionnaires, and review of medical records or patient through interview or telephone call. Most studies adjusted for potential confounders, but the factors adjusted for varied across studies. Loss to follow-up was unclear in 30 studies, and 12 studies had 10% or more loss to follow-up or missing data. The study reference group and studies included for each analysis are shown in Data S7.

Sleep Duration and All-Cause Mortality

Numeric results of analyses are shown in Tables 2 and 3. For the spline analysis, a total of 30 studies* reported data that could be used for the all-cause mortality analysis. When spline analysis was applied using a linear model, incremental deviation <7 hours of self-reported sleep was not associated with increased risk of all-cause mortality, but sleep durations >8 hours were associated with increased risk of all-cause mortality (Figure 2). The cubic spline analysis model is shown in Data S8.

Pooled risk of all-cause mortality for the entire cohort (Figure 2, Data S9) and the subgroup of men and women only are shown in Data S10. There were a total of 39 studies included in the analysis.** The funnel plot for sleep duration and mortality did not suggest that there was publication bias. Deviation from self-reported sleep duration of 7 or 8 hours appeared to be associated with all-cause mortality, where

References 11, 21, 23, 25, 26, 29, 32, 33, 36, 41, 44, 47–49, 52, 55–57, 60, 64, 66, 68, 70, 71, 79, 80, 84, 86–88.

References 11, 21, 23, 25–27, 29, 32–34, 36, 39–41, 44, 46–49, 51–54, 56, 57, 61, 64, 66, 68, 70–72, 77, 79, 80, 84, 86–88.
### Table 1. Study Design and Demographics Table

| Study ID     | Design; Country; Year | No. of Participants | Mean Age, y | % Male | Participant Inclusion Criteria |
|--------------|-----------------------|---------------------|-------------|--------|--------------------------------|
| Akersted, 2017<sup>21</sup> | Prospective cohort study; Sweden; 1997–2010 | 43 868 | 51 | 36 | Participants were aged >18 y in the Swedish National March study. |
| Amagai, 2010<sup>22</sup> | Prospective cohort study; Japan; April 1992 to July 1995 | 11 367 | 55 | 39 | Participants were adults of varying ages in 12 rural areas of Japan from the Jichi Medical School Cohort Study. |
| Aurora, 2016<sup>23</sup> | Prospective cohort study; USA; 1995–2011 | 5784 | 64 | 46 | Participants were aged 40 y and not treated for sleep-disordered breathing in the Sleep Heart Health Study. |
| Ayas, 2003<sup>24</sup> | Prospective cohort study; USA; 1986–1996 | 71 617 | Unclear | 0 | Participants were US female health professionals aged 45 to 65 y who were enrolled in the Nurses’ Health Study. |
| Bellavia, 2014<sup>25</sup> | Prospective cohort study; Sweden; 1998–2012 | 70 973 | Unclear | 53 | Participants were Swedish males and aged 45 to 79 y and females aged 39 to 76 y from the population-based Cohort of Swedish Men and the Swedish Mammography Cohort. |
| Burazeri, 2003<sup>26</sup> | Prospective cohort study; Israel; 1985 with up to 11 years’ follow-up | 1842 | Unclear | 46 | Participants were aged >50 y in West Jerusalem in the Kiryat Yovel Community Health Study. |
| Cai, 2015<sup>27</sup> | Prospective cohort study; China; 1996–2010 | 113 138 | 54 | 41 | Participants were Chinese men and women in Shanghai, China in the Shanghai Women’s Health Study and the Shanghai Men’s Health Study. |
| Canivet, 2014<sup>28</sup> | Prospective cohort study; Sweden; 1991–2005 | 13 617 | Unclear | 43 | Participants were all people between the ages of 45 and 65 residing in Malmo, Sweden from the Malmo Diet and Cancer Study 1991. |
| Castro-Costa, 2011<sup>29</sup> | Prospective cohort study; Brazil; 1997–2005 | 1512 | Median 69 | 38 | Participants were all residents of Bambui city, Brazil aged ≥60 years on January 1, 1997 and part of the Bambui Cohort Study. |
| Chandola, 2010<sup>30</sup> | Prospective cohort study; England; 1985–1988 | 10 308 | Unclear | 67 | Participants were adults aged 35 to 55 y from 20 London-based civil service departments in the Whitehall II Cohort. |
| Chen, 2008<sup>31</sup> | Prospective cohort study; USA; 1994–1998 | 93 175 | Unclear | 0 | Participants were postmenopausal women aged 50 to 79 y from all over the United States in the Women’s Health Initiative Observational study cohort. |
| Chen, 2013<sup>32</sup> | Prospective cohort study; Taiwan; 1999–2002 | 4064 | 73.8 | 56 | Participants were residents of the Shih-Pai area of Taipei, Taiwan who were aged >65 y and part of the Shih-Pai Sleep Study. |
| Chien, 2010<sup>33</sup> | Prospective cohort study; Taiwan; 1990–1991 | 3430 | 54.8 | 50 | Participants were adults aged >35 years in the Chin-Shan Community Cardiovascular Cohort study and of Chinese ethnicity living in Chin-Shan township, Taiwan. |
| Cohen-Mansfeld, 2012<sup>24</sup> | Prospective cohort study; Israel; 1989–1992 | 1166 | 83 | 55 | Participants were older Jewish adults aged >75 y in the Cross-Sectional and Longitudinal Aging Study. |
| Ensrud, 2012<sup>35</sup> | Prospective cohort study; USA; 2003–2005 | 2505 | 76 | 100 | Participants were nonfrail males aged >65 y, recruited by the prospective Osteoporotic Fractures in Men study. |
| Gangwisch, 2008<sup>26</sup> | Prospective cohort study; USA; 1982–1992 | 9789 | Unclear | 37 | Participants were men and women aged 25 to 74 y in the NHANES I epidemiological follow-up study. |

Continued
| Study ID       | Design; Country; Year     | No. of Participants | Mean Age, y | % Male | Participant Inclusion Criteria                                                                                                                                 |
|---------------|---------------------------|---------------------|-------------|--------|--------------------------------------------------------------------------------------------------------------------------------|
| Garde, 201337 | Prospective cohort study; Denmark; 1970-2001 | 5249                | 49          | 100    | Participants were in the Copenhagen Male Study who were all men aged 40 to 59 y at 14 companies were invited. |
| Gianfagna, 201638 | Prospective cohort study; Italy; 1986-2008 | 2277                | 51          | 100    | Participants were men aged 35 to 74 y and CVD free in the MONICA-Brianza and PAMELA population based cohorts. |
| Goto, 201339   | Prospective cohort study; Japan; 1987–1999    | 724                 | Unclear     | 65     | Participants were aged ≥65 y in Okinawa Japan.                                                                                                    |
| Hale, 201340   | Prospective cohort study; USA; 1993–2009      | 3942                | 62          | 0      | Participants were in the Women’s Health Initiative clinical trial and observational study who were postmenopausal women aged 50 to 79 y and did not have history of CHD. |
| Hall, 201551   | Prospective cohort study; USA; 1997 start follow-up of 9 years | 3013                | 73.6        | 48.6   | Participants were adults in the Health, Aging and Body Composition Study.                                                                            |
| Hamazaki, 201142 | Prospective cohort study; Japan; 1994–2008    | 2282                | 44          | 100    | Participants were men aged 35 to 54 y at a light metal factory (Japan) who did not have previous cardiovascular events or missing information at baseline survey. |
| Helbig, 201543  | Prospective cohort study; Germany; 1984–2001   | 17 604              | 48          | 50     | Participants were age 25 to 74 y in the Monitoring Trends and Determinants in Cardiovascular Disease/Cooperative Health Research in the Region of Augsburg study. |
| Heslop, 200254  | Prospective cohort study; Scotland; 1970–1995  | 3030                | Unclear     | 85     | Participants were working Scottish men and women recruited between 1970 and 1973.                                                                 |
| Hoevenaar-Blom, 201112 | Prospective cohort study; Netherlands; 1993–2012 | 20 432              | 42          | 45     | Participants were aged 20 to 65 y in the MORGEN study.                                                                                                  |
| Huang, 201345   | Prospective cohort study; Taiwan; 1999–2010   | 1901                | Unclear     | 51     | Participants were aged ≥65 y in the Elderly Nutrition and Health Survey in Taiwan.                                                                     |
| Hublin, 200746  | Prospective cohort study; Finland; 1975–2003   | 21 268              | 41          | 48     | Participants were in Finnish Twin Cohort who were all Finnish twin pairs of the same sex born before 1958 with both co-twins alive in 1975. |
| Ikehara, 200947 | Prospective cohort study; Japan; 1988–2003    | 98 634              | Unclear     | 42     | Participants were in the Japan Collaborative Cohort Study for Evaluation of Cancer Risk where were aged 40 to 79 y and living in Japan.                     |
| Jung, 201348    | Prospective cohort study; USA; 1984–2001      | 2001                | 74          | 44     | Participants were in the community-dwelling adults aged 60 to 96 y in The Rancho Bernardo Study.                                                        |
| Kakizaki, 201349 | Prospective cohort study; Japan; 1994–2008    | 49 256              | 60          | 48     | Participants were aged 40 to 79 y in the Ohsaki Cohort Study.                                                                                         |
| Kawachi, 201650 | Prospective cohort study; Japan; 1992–2008    | 27 896              | 54          | 54     | Participants were men and women aged ≥35 y in the Takayama Cohort Study.                                                                             |
| Kim, 201351     | Prospective cohort study; USA; 1993–2007      | 135 685             | Unclear     | 46     | Participants were aged 45 to 75 y in the Multietnic Cohort Study from Hawaii and Los Angeles.                                                          |
| Kojima, 200052  | Prospective cohort study; Japan; 1982–1996    | 5322                | 47          | 46     | Participants were aged 20 to 76 y from Shirakawa town, Japan.                                                                                          |
| Kripke, 200253  | Prospective cohort study; USA; 1982–1988      | 1 116 936           | 57          | 43     | Participants were aged 30 to 102 y in the Cancer Prevention Study II mainly friends/relatives of American Cancer Society volunteers. |
Table 1. Continued

| Study ID   | Design; Country; Year | No. of Participants | Mean Age, y | % Male | Participant Inclusion Criteria                                                                 |
|------------|-----------------------|---------------------|-------------|--------|-------------------------------------------------------------------------------------------------|
| Lee, 201455| Prospective cohort study; Taiwan; 1993–2003 | 3427               | 74          | 51     | Participants were ≥64 y in the Survey of Health and Living Status of the Elderly in Taiwan.      |
| Lee, 201756| Prospective cohort study; Hong Kong; 2001–2010 | 937                | 65          | 55     | Participants were Taiwanese aged ≥53 y in the Social Environment and Biomarkers of Aging Study. |
| Leng, 20159 | Prospective cohort study; Taiwan; 2006–2010 | 9692               | 62          | 46     | Participants were adults aged 42 to 81 y in the European Prospective Investigation into Cancer-Norfolk cohort. |
| Li, 201357  | Prospective cohort study; Japan; 1983–1990  | 12 489             | Unclear     | 38     | Participants were residents aged 20 to 79 y in the Minami Saku area of Japan who were a part of the SAKUCESS project. |
| Liu, 201448 | Prospective cohort study; USA; 1971–2007    | 3381               | 45          | 48     | Participants were aged >30 y and were free from CHD in the Framingham Offspring Study.           |
| Magee, 201158 | Prospective cohort study; Australia; 2006–2009 | 218 155           | 63          | 47     | Participants were Australian adults aged ≥45 y, residing in the state of New South Wales and part of the 45 and Up study. |
| Magee, 201359 | Prospective cohort study; Australia; 2006–2009 | 227 815          | Unclear     | 46.3   | Participants were Australian adults aged ≥45 y, residing in the state of New South Wales and part of the 45 and Up study. |
| Mallon, 200261 | Prospective cohort study; Sweden; 1983–1995 | 1870               | 56          | 48     | Participants were a random adults aged 45 to 65 y in the population register of the County of Dalarna in Sweden. |
| Martin, 201162 | Prospective cohort study; USA; Unclear     | 245                | 81          | 62     | Participants were adults aged ≥65 y admitted to postacute rehabilitation sites in the Los Angeles area in the USA. |
| Meisinger, 200763 | Prospective cohort study; Germany; 1984–1995 | 6896              | 58          | 50.9   | Participants were German adults aged 45 to 74 y who were part of the MONICA Augsburg project.       |
| Mesas, 201064 | Prospective cohort study; Spain; 2001–2008 | 3820               | 71.8        | 44     | Participants were noninstitutionalized adults aged ≥60 y living in Spain.                         |
| Pan, 201465  | Prospective cohort study; Singapore; 1993–1998 | 63 257            | 57          | 44     | Participants were Chinese adults in Singapore aged 45 to 74, recruited from Hokkiens and Cantonese dialect groups residing in government housing estates. |
| Patel, 200466 | Prospective cohort study; USA; 1986–2000   | 82 969            | 53          | 0      | Participants were women aged 30 to 55 y and residing in 11 US states that were part of the Nurses’ Health Study. |
| Pollak, 199067 | Prospective cohort study; USA; 1984–1985  | 1855               | 75          | Unclear | Participants were elderly residents of an urban community aged 65 to 98 y.                          |
| Qiu, 201168  | Prospective cohort study; China; 2005–2008  | 12 671            | 86          | 57     | Participants were elderly Chinese adults from 22 provinces in China in the Chinese Longitudinal Healthy Longevity Survey. |
| Qureshi, 199769 | Prospective cohort study; USA; 1982–1992  | 7844              | Unclear     | 36     | Participants were US civilian noninstitutionalized adults aged >31 y and in the NHANES I Epidemiologic Follow-up Study (NHFESt). |
| Rhee, 201270  | Prospective cohort study; Korea; 1992–2008  | 14 533            | 51          | 100    | Participants were male subjects aged 40 to 59 y in the Seoul Male Cohort Study.                   |

Continued
### Table 1. Continued

| Study ID | Design; Country; Year | No. of Participants | Mean Age, y | % Male | Participant Inclusion Criteria |
|----------|-----------------------|---------------------|-------------|--------|--------------------------------|
| Rod, 2014<sup>71</sup> | Prospective cohort study; UK; 1985–2010 | 9098 | 45 | 67 | Participants were in the Whitehall II Cohort Study who were London-based office staff aged 35 to 55 y working in 20 civil service departments in 1985. |
| Ruigomez, 1995<sup>72</sup> | Prospective cohort study; Spain; 1986–1991 | 1219 | Unclear | 39 | Participants were an elderly population in the 1986 Health Interview Survey of Barcelona. |
| Ruiter Petrov, 2014<sup>73</sup> | Prospective cohort study; USA; 2003–2010 | 5666 | 61 | 44 | Participants were aged ≥45 y in the Reasons for Geographic And Racial Differences in Stroke study. |
| Sands-Lincoln, 2013<sup>74</sup> | Prospective cohort study; USA; 1993–2009 | 86 329 | 63 | 0 | Participants were in the Women’s Health Initiative clinical trial and observational study who were postmenopausal women aged 50 to 79 y and did not have a history of CHD. |
| Shankar, 2008<sup>75</sup> | Prospective cohort study; Singapore; 1993–2006. | 58 044 | 56 | 44 | Participants were Chinese adults aged 45 to 75 y in the Singapore Chinese Health Study. |
| Song, 2016<sup>76</sup> | Prospective cohort study; China; 2006–2010 | 95 203 | 51 | 79 | Participants were aged 18 to 98 y in the Kailuan study. |
| Stone, 2009<sup>77</sup> | Prospective cohort study; USA; Unclear | 6107 | 80 | 50 | Participants were community-dwelling older adults participating in the Study of Osteoporotic Fractures and the Outcomes of Sleep Disorders in Older Men Study. |
| Strand, 2016<sup>78</sup> | Prospective cohort study; Taiwan; 1998–2011 | 392 164 | 40 | 49 | Participants were Taiwanese adults aged 20 y who were participants in a health check-up program run by MJ Health Management Institution. |
| Suzuki, 2009<sup>79</sup> | Prospective cohort study; Japan; 1999–2006 | 12 601 | 74 | 51 | Participants were elderly residents aged 65 to 85 y in the Shizuoka Study. |
| Tamakoshi, 2004<sup>80</sup> | Prospective cohort study; Japan; 1988–1999 | 104 010 | 58 | 42 | Participants were aged 40 to 79 y in the Japan Collaborative Cohort Study on Evaluation of Cancer Risk study. |
| Tsubono, 1993<sup>81</sup> | Prospective cohort study; Japan; 1988–1992 | 4318 | Unclear | 40 | Participants were aged ≥40 y in Japan who participated in the annual health examination program implemented by the Town Council. |
| Tu, 2012<sup>82</sup> | Prospective cohort study; China; 1997–2006 | 68 832 | 60 | 0 | Participants were women aged 40 to 70 y in the Shanghai Women’s Health Study. |
| Twig, 2016<sup>83</sup> | Prospective cohort study; Israel; unclear | 23 690 | 30 | 100 | Participants were men aged >25 y in the Israeli Defense Forces who were in the MELANY cohort study. |
| Von Ruesten, 2012<sup>84</sup> | Prospective cohort study; Germany; 1994–2007 | 23 620 | 49 | 39 | Participants were in the European Prospective Investigation into Cancer and Nutrition (EPIC) study in Potsdam. |
| Wang, 2016<sup>85</sup> | Prospective cohort study; China; 2006–2010 | 95 903 | 51 | 80 | Participants were aged 18 to 98 y in the Kailuan study. |
| Werle, 2011<sup>86</sup> | Prospective cohort study; Brazil; 1994–2009 | 187 | 84 | 36 | Participants were aged >80 y in the city of Veranopolis, Brazil. |
| Westerlund, 2013<sup>87</sup> | Prospective cohort study; Sweden; 1997–2010 | 41 192 | Unclear | 35 | Participants were aged ≥18 y in the Swedish National March Cohort Study. |
| Wingard, 1983<sup>88</sup> | Prospective cohort study; USA; 1965–1974 | 6928 | Unclear | 47 | Participants were aged 30 to 69 y of age in 1965 in California. |
| Xiao, 2014<sup>89</sup> | Prospective cohort study; USA; 1995–2011 | 239 896 | 63 | 56 | Participants were aged 51 to 72 y in the NIH AARP Diet and Health Study. |
longer sleep durations are associated with greater mortality compared with small increases for shorter durations. The similar J-shaped relationship was observed for the subgroup of men and women.

Sleep Duration and CHD Mortality and CHD

A total of 5,27,47,49,75,78 and 12 studies*** were included in spline analysis for CHD mortality and CHD, respectively. Linear spline analysis failed to demonstrate any significant difference for both outcomes for self-reported shorter and longer sleep durations (Figure 3, cubic model in Data S8).

For the meta-analysis, there were 7 studies37,47,49,51,61,75,78 (Data S11) and 15 studies**** (Data S12) for CHD mortality and CHD, respectively. Although there were fewer studies, a similar J-shaped pattern was observed where there was greater risk of CHD mortality and events with incremental deviation from the reference 7 to 8 hours of self-reported sleep (a modest increase for 6 hours and greater increase for ≤5 hours; Data S10). The funnel plot for self-reported sleep duration and CHD mortality suggested a possible publication bias whereas for CHD the plot did not suggest that there was a publication bias.

Sleep Duration and Stroke Mortality and Stroke

Linear spline analysis for stroke mortality and stroke included 3,47,49,65 and 9,22,31,42,43,50,69,76,83 studies, respectively. There was no difference in stroke events associated with self-reported sleep duration shorter or longer than 7 hours, but a moderate increase in stroke mortality if sleep duration was >7 hours (Figure 3, Data S8).

Meta-analysis of 5 studies37,47,49,51,65 were included in the analysis of stroke mortality (Data S10). For stroke events, there were 13 studies.† The funnel plot for sleep duration and stroke mortality did not suggest a publication bias. For stroke mortality, there appeared to be no difference in events with self-reported sleep duration <7 hours, but significant and moderate increase in events with longer sleep duration >8 hours (Data S13). However, for stroke events, the increase in event rates are preserved for both sleep duration <7 hours (modest for 6 hours and a greater increase for ≤5 hours) and a moderate increase for >8 hours (Data S14). The funnel plot for sleep duration and stroke did not suggest a publication bias.

Sleep Duration and Cardiovascular Mortality and CVD

Spline analysis using linear models did not shown any difference in events with shorter duration than 7 hours for both cardiovascular mortality (8 studies)11,25,44,47,49,71,87,88 and CVD (7 studies).8,12,22,33,38,42,74 However, longer self-reported sleep duration >7 hours appeared to be associated with a moderate increase in greater stroke mortality (cubic model shown in Data S8).

There were 16 studies‡ (Data S15) that evaluated CVD mortality and 8 studies8,12,22,28,33,38,42,74 (Data S16) that evaluated CVD events. The J-shaped pattern was observed for self-reported sleep duration and CVD mortality, but this was not the case for CVD events, but there were fewer studies in the event analysis. The funnel plot for sleep duration and CVD mortality and CVD did not suggest a publication bias. Incremental decrease in hours of sleep was associated with significant increase in mortality (Data S10).

Sleep Quality and Mortality and Adverse Cardiovascular Outcomes

A total of 17 studies§ were included in the analysis of subjective sleep quality and adverse outcomes (Data S10 and Data S17). For all-cause mortality, there were 12,652 deaths...
Table 2. Study Cohort, Follow-up and Results for Studies With Authors Akersted to Akersted

| Study ID          | Follow-up Duration | Outcomes and Crude Rate of Outcomes | Results                                                                 |
|-------------------|--------------------|-------------------------------------|-------------------------------------------------------------------------|
| Akersted, 201721  | 13 y               | All-cause mortality: 3548/39 191     | Sleep duration and mortality: ≤5 h: aHR 1.12 (0.99–1.27), 6 h: aHR 0.98 (0.88–1.09), 7 h: aHR 1.00, ≥8 h: aHR 1.10 (1.00–1.20). |
| Amagai, 201022    | 10.7 y             | CVD events: 481/11 367. MI: 80/11 367. Stroke: 411/11 367 | Sleep duration and CVD in males: ≤5.9 h: aHR 2.14 (1.11–4.13), 6.0 to 6.9 h: aHR 1.04 (0.61–1.76), 7.0 to 7.9 h: aHR 1.00, 8.0 to 8.9 h: aHR 0.98 (0.69–1.40), ≥9.0 h: aHR 1.33 (0.93–1.92).  
Sleep duration and CVD in females: ≤5.9 h: aHR 1.46 (0.70–3.04), 6.0 to 6.9 h: aHR 0.64 (0.38–1.10), 7.0 to 7.9 h: aHR 1.00, 8.0 to 8.9 h: aHR 0.85 (0.60–1.20), ≥9.0 h: aHR 1.28 (0.98–1.87).  
Sleep duration and MI in men: ≤5.9 h: aHR 1.78 (0.50–6.28), 6.0 to 6.9 h: aHR 0.77 (0.25–2.33), 7.0 to 7.9 h: aHR 1.00, 8.0 to 8.9 h: aHR 0.69 (0.34–1.41), ≥9.0 h: aHR 0.99 (0.47–2.06).  
Sleep duration and MI in women: ≤5.9 h: aHR 4.93 (1.31–18.61), 6.0 to 6.9 h: aHR 0.59 (0.13–2.73), 7.0 to 7.9 h: aHR 1.00, 8.0 to 8.9 h: aHR 0.59 (0.21–1.66), ≥9.0 h: aHR 0.84 (0.27–2.62).  
Sleep duration and stroke in men: ≤5.9 h: aHR 2.00 (0.93–4.31), 6.0 to 6.9 h: aHR 1.13 (0.63–2.03), 7.0 to 7.9 h: aHR 1.00, 8.0 to 8.9 h: aHR 1.03 (0.69–1.53), ≥9.0 h: aHR 1.39 (0.92–2.10).  
Sleep duration and stroke in women: ≤5.9 h: aHR 0.97 (0.39–2.41), 6.0 to 6.9 h: aHR 0.68 (0.39–1.18), 7.0 to 7.9 h: aHR 1.00, 8.0 to 8.9 h: aHR 0.86 (0.60–1.23), ≥9.0 h: aHR 1.29 (0.86–1.91). |
| Aurora, 201623    | 10.8 y             | All-cause mortality: 1509/5784       | Sleep duration and mortality: ≤7 h: aHR 0.98 (0.87–1.10), 7 to 8 h: aHR 1.00, ≥9 h: aHR 1.25 (1.05–1.47). |
| Ayas, 200324      | 10 y               | CHD: 934/71 617                     | Sleep duration and CHD: ≤5 h: aOR 1.39 (1.05–1.84), 6 h: aOR 1.18 (0.98–1.43), 7 h: aOR 1.10 (0.92–1.31), 8 h: aOR 1.00, ≥9 h: aOR 1.37 (1.02–1.85). |
| Bellavia, 201425  | 15 y               | All-cause mortality 13 450/70 973. CVD mortality: 3981/70 973 | Sleep duration and all-cause mortality: <6 h: aHR 1.25 (1.13–1.37), 6 to 6.5 h: aHR 1.10 (1.04–1.17), 6.6 to 7.4 h: aHR 1.00 (reference), 7.5 to 8 h: aHR 1.03 (0.98–1.08), ≥8 h: aHR 1.14 (1.05–1.24).  
Sleep duration and CVD mortality: <6 h: aHR 1.44 (1.20 to 1.73), 6 to 6.5 h: aHR 1.23 (1.09–1.38), 6.6 to 7.4 h: aHR 1.00, 7.5 to 8 h: aHR 1.02 (0.92–1.12), ≥8 h: aHR 1.11 (0.95–1.31). |
| Burazeri, 200326  | 10 y               | All-cause mortality: 403/1842       | Total sleep duration and all-cause mortality in men: ≤6 h: aHR 1.00, 6 to 8 h: aHR 1.41 (0.83–2.39), ≥8 h: aHR 2.13 (1.23–3.71).  
Total sleep duration and all-cause mortality in women: ≤6 h: aHR 1.00, 6 to 8 h: aHR 0.63 (0.42–0.97), ≥8 h: aHR 0.80 (0.51–1.24).  
Total sleep duration and CVD mortality in men: ≤6 h: aHR 1.00, 6 to 8 h: aHR 1.54 (0.75–3.15), ≥8 h: aHR 2.02 (1.01–4.03).  
Total sleep duration and CVD mortality in women: ≤6 h: aHR 1.00, 6 to 8 h: aHR 0.69 (0.37–1.29), ≥8 h: aHR 0.79 (0.42–1.48). |
| Cai, 201527       | Median 6 to 7 y    | All-cause mortality: 4277/113 138    | Sleep duration and all-cause mortality: 4 to 5 h: aHR 1.11 (1.00–1.23), 6 h: aHR 1.06 (0.97–1.16), 7 h: aHR 1.00, 8 h: aHR 1.15 (1.05–1.26), 9 h: aHR 1.34 (1.17–1.54), ≥10 h: aHR 1.81 (1.59–2.06).  
Sleep duration and all-cause mortality in men: 4 to 5 h: aHR 1.06 (0.90–1.25), 6 h: aHR 1.07 (0.94–1.23), 7 h: aHR 1.23 (0.99–1.54).  
Sleep duration and all-cause mortality in women: 4 to 5 h: aHR 1.06 (0.90–1.25), 6 h: aHR 1.07 (0.94–1.23), 7 h: aHR 1.23 (0.99–1.54). |
## Table 2. Continued

| Study ID | Follow-up Duration | Outcomes and Crude Rate of Outcomes | Results |
|----------|--------------------|------------------------------------|---------|
|          |                    |                                    | 1.00, 8 h: aHR 1.13 (1.00–1.28), 9 h: aHR 1.34 (1.10–1.62), ≥10 h: aHR 1.55 (1.29–1.86).  
Sleep duration and all-cause mortality in women: 4 to 5 h: aHR 1.15 (1.01–1.32), 6 h: aHR 1.06 (0.94–1.20), 7 h: aHR 1.00, 8 h: aHR 1.17 (1.04–1.32), 9 h: aHR 1.36 (1.13–1.64), ≥10 h: aHR 2.11 (1.77–2.52).  
Sleep duration and cardiovascular mortality: 4 to 5 h: aHR 1.05 (0.87–1.26), 6 h: aHR 1.10 (0.94–1.29), 7 h: aHR 1.00, 8 h: aHR 1.22 (1.05–1.43), 9 h: aHR 1.47 (1.17–1.85), ≥10 h: aHR 2.04 (1.65–2.53).  
Sleep duration and cardiovascular mortality in men: 4 to 5 h: aHR 1.09 (0.82–1.46), 6 h: aHR 1.06 (0.83–1.34), 7 h: aHR 1.00, 8 h: aHR 1.25 (1.00–1.56), 9 h: aHR 1.68 (1.23–2.30), ≥10 h: aHR 1.58 (1.14–2.18).  
Sleep duration and cardiovascular mortality in women: 4 to 5 h: aHR 1.15 (1.01–1.32), 6 h: aHR 1.06 (0.94–1.20), 7 h: aHR 1.00, 8 h: aHR 1.17 (1.04–1.32), 9 h: aHR 1.36 (1.13–1.64), ≥10 h: aHR 2.11 (1.77–2.52).  
Sleep duration and cardiovascular mortality in men: 4 to 5 h: aHR 1.02 (0.80–1.30), 6 h: aHR 1.12 (0.91–1.39), 7 h: aHR 1.00, 8 h: aHR 1.20 (0.96–1.50), 9 h: aHR 1.28 (0.91–1.82), ≥10 h: aHR 2.64 (1.99–3.52).  
Sleep duration and stroke mortality: 4 to 5 h: aHR 0.91 (0.70–1.18), 6 h: aHR 0.99 (0.79–1.23), 7 h: aHR 1.00, 8 h: aHR 1.28 (1.04–1.58), 9 h: aHR 1.31 (0.94–1.82), ≥10 h: aHR 2.35 (1.78–3.09).  
Sleep duration and stroke mortality in men: 4 to 5 h: aHR 0.93 (0.62–1.40), 6 h: aHR 0.78 (0.55–1.10), 7 h: aHR 1.00, 8 h: aHR 1.20 (0.89–1.62), 9 h: aHR 1.62 (1.06–2.48), ≥10 h: aHR 1.73 (1.14–2.64).  
Sleep duration and stroke mortality in women: 4 to 5 h: aHR 0.92 (0.65–1.29), 6 h: aHR 1.14 (0.85–1.52), 7 h: aHR 1.00, 8 h: aHR 1.36 (1.01–1.82), 9 h: aHR 0.98 (0.58–1.66), ≥10 h: aHR 3.09 (2.14–4.47).  
Canivet, 201428 | 14 y | Unclear | Night-time sleep duration and all-cause mortality: <6 h: aHR 1.1 (0.96–1.3), 7 to 8 h: aHR 1.0, ≥9 h:aHR 1.3 (1.01–1.7).  Sleep duration and cardiovascular events in men: ≤6 h: aHR 1.1 (0.96–1.3), 7 to 8 h: aHR 1.0, ≥9 h:aHR 1.3 (1.01–1.7).  Sleep duration and cardiovascular events in women: ≤6 h: aHR 1.1 (0.96–1.3), 7 to 8 h: aHR 1.0, ≥9 h:aHR 1.3 (1.01–1.7). |
| Castro-Costa, 201129 | Unclear | All-cause mortality: 440/1512 | Night-time sleep duration and all-cause mortality: <6 h: aHR 1.09 (0.78–1.53), 6 to 7 h: aHR 0.84 (0.60–1.17), 7 to 8 h: aHR 1.00 (reference), 8 to 9 h: aHR 1.31 (0.97–1.78), ≥9 h: aHR 1.53 (1.12–2.09).  
Chandola, 201030 | 15 y | CHD mortality, MI, angina: 1205/8998 | Sleep duration and CHD mortality, MI and angina: <5 h: aRR 1.05 (0.92–1.20), 6 h: aRR 0.98 (0.83–1.18), 7 h: aRR 1.00, <8; aRR 0.99 (0.77–1.27).  Poor sleep quality (more than usual restless, disturbed nights) and CHD mortality, MI, and angina: aRR 1.36 (1.10–1.68).  
Chen, 200831 | 7.5 y | Ischaemic stroke: 1166/93 175 | Sleep duration and ischemic stroke: <6 h: aHR 1.14 (0.97–1.33), 7 h: aHR 1.00, 8 h: aHR 1.24 (1.04–1.47), ≥9 h: aHR 1.70 (1.32–2.21).  
Chen, 201332 | 9 y | All-cause mortality: 1004/4064. CVD mortality: 259/4064 | Sleep duration and all-cause mortality: <4 h: aHR 1.00 (0.75–1.33), 5 h: aHR 0.92 (0.74–1.15), 6 h: aHR 0.88 (0.73–1.06), 7 h: aHR 1.00, 8 h: aHR 1.26 (1.04–1.53), ≥9 h: aHR 1.66 (1.28–2.17).  
Sleep duration and CVD mortality: <4 h: aHR 1.05 (0.61–1.79), 5 h: aHR 0.95 (0.62–1.48), 6 h:aHR 0.79 (0.54–1.16), 7 h: aHR 1.00, 8 h: aHR 1.36 (0.92–2.01), ≥9 h: aHR 2.36 (1.46–3.80).  Poor sleep quality (subjective) and all-cause mortality: aHR 0.81 (0.47–1.38).  Poor sleep quality (subjective) and CVD mortality: aHR 0.60 (0.19–1.93). |

DOI: 10.1161/JAHA.118.008552  
Journal of the American Heart Association 10
### Table 2. Continued

| Study ID          | Follow-up Duration | Outcomes and Crude Rate of Outcomes | Results                                                                 |
|-------------------|--------------------|-------------------------------------|-------------------------------------------------------------------------|
| Chien, 2010       | Median 15.9 y      | All-cause mortality: 901/3430. CVD events: 420/3430 | Sleep duration and all-cause mortality: <5 h: aRR 1.15 (0.9--1.46), 6 h: aRR 0.97 (0.79--1.21), 7 h: aRR 1.04 (0.86--1.27), ≥9 h: aRR 1.34 (1.08--1.67). Sleep duration and CVD event: <5 h: aRR 0.94 (0.65--1.35), 6 h: aRR 0.91 (0.67--1.24), 7 h: aRR 1, 8 h: aRR 1.05 (0.80--1.39), ≥9 h: aRR 1.12 (0.81--1.55). |
| Cohen-Mansfeld, 2012 | 20 y               | All-cause mortality: 1108/1166 | Sleep duration and mortality: <7 h: aHR 0.98 (0.84--1.13), 7 to 9 h: 1.00, ≥9 h: aHR 1.32 (1.09--1.58). |
| Ensrud, 2012       | 3.4 y              | All-cause mortality: 180/2505       | Poor sleep quality (PSQI score >5) and all-cause mortality: >5 81/1018 vs ≤5 99/1487, aOR 1.02 (0.73--1.42). Sleep duration and all-cause mortality: ≤5 h: 21/269 vs 159/2236, aOR 1.08 (0.65--1.80). |
| Gangwisch, 2008   | Up to 10 y         | All-cause mortality: 1877/9789      | Sleep duration and all-cause mortality: ≤5 h: aHR 1.17 (0.99--1.39), 6 h: aHR 0.95 (0.81--1.11), 7 h: aHR 1.00, 8 h: aHR 1.23 (1.08--1.39), ≥9 h: aHR 1.34 (1.15--1.56). |
| Garde, 2013       | 30 y               | All-cause mortality: 2643/5249. Ischaemic heart disease mortality: 587/5249 | Sleep duration on all-cause mortality in men: <6 h: aHR 1.06 (0.90--1.25), 6 to 7 h: aHR 1.00. >6 h: aHR 0.99 (0.84 to 1.09). Sleep duration and ischemic heart disease mortality in men: <6 h: aHR 1.46 (1.07--2.00), 6 to 7 h: aHR 1.00. ≥8 h: aHR 1.20 (0.97--1.49). |
| Gianfagna, 2016   | Median 17 y        | CVD event: 293/2277. CHD event: 214/2277 | Sleep duration and CVD event: ≤6 h: aHR 1.14 (0.84--1.53), 7 to 8 h: aHR 1.00, ≥9 h: aHR 1.55 (1.08--2.21). Sleep duration and CHD event: ≤6 h: aHR 1.14 (0.80--1.61), 7 to 8 h: aHR 1.00, ≥9 h: aHR 1.32 (0.85--2.07). Sleep disturbance on CVD event vs none/some: moderate aHR 1.14 (0.74--1.77), severe aHR 1.80 (1.07--3.03). Sleep disturbance on CHD event vs none/some: moderate aHR 1.35 (0.83--2.21), severe aHR 1.83 (0.98--3.41). |
| Goto, 2013        | 12 y               | All-cause mortality: 305/724        | Sleep duration and all-cause mortality in men: aHR <6 h: aHR 1.29 (0.50--3.34), 6 to 7 h: aHR 1.00, >7 h: aHR 1.54 (0.92--2.58). Sleep duration and all-cause mortality in women: aHR <6 h: aHR 2.62 (1.36--5.07), 6 to 7 h: aHR 1.00, >7 h: aHR 1.40 (0.91--2.15). |
| Hale, 2013        | Up to 16 y         | All-cause mortality: 335/3942. CHD event: 132/3942 | Sleep duration and all-cause mortality: ≤5 h: aOR 1.01 (0.68--1.51), 6 h: aOR 0.94 (0.71--1.24), 7 to 8 h: aOR 1.00, ≥9 h: aOR 1.55 (0.92--2.60). Sleep duration and CHD: ≤5 h: aOR 1.09 (0.63--1.88), 6 h: aOR 0.66 (0.42--1.04), 7 to 8 h: aOR 1.00, ≥9 h: aOR 1.61 (0.92--3.83). |
| Hall, 2015        | 9 y                | All-cause mortality: 953/3075       | Sleep duration and all-cause mortality: ≤6 h: aHR 1.06 (0.83--1.34), 6 to 7 h: aHR 1.00 (0.82--1.22), 7 to 8 h: aHR 1.00, ≥8 h: aHR 1.10 (0.91--1.33), >8 h: aHR 1.23 (0.93--1.63). |
| Hamazaki, 2011    | 14 y               | CVD events: 64/2282. Stroke: 30/2282. Coronary events: 27/2282 | Sleep duration and CVD events: <6 h: aHR 3.49 (1.30--9.40), 6 to 6.9 h: aHR 1.11 (0.55--2.25), 7 to 7.9 h: aHR 1.00, ≥8 h: aHR 1.71 (0.90--3.24). Sleep duration and stroke: <6 h: aHR 1.84 (0.23--14.90), 6 to 6.9 h: aHR 0.96 (0.30--3.10), 7 to 7.9 h: aHR 1.00, ≥8 h: aHR 2.25 (0.91--5.57). Sleep duration and coronary events: <6 h: aHR 4.95 (1.31--18.73), 6 to 6.9 h: aHR 1.12 (0.40--3.13), 7 to 7.9 h: aHR 1.00 (reference), ≥8 h: aHR 1.78 (0.67--4.76). |
| Study ID          | Follow-up Duration | Outcomes and Crude Rate of Outcomes | Results                                                                 |
|-------------------|--------------------|-------------------------------------|--------------------------------------------------------------------------|
| Helbig, 2015      | 14 y               | Stroke: 917/17 604                  | Sleep duration and strokes in men: ≤5 h: aHR 1.36 (0.95–1.94), 6 h:    |
|                   |                    |                                     | aHR 0.92 (0.70–1.22), 7 to 8 h: aHR 1.00, 9 h: aHR 1.05 (0.78–1.43),  |
|                   |                    |                                     | ≥10 h: aHR 1.38 (0.98–1.94). Sleep duration and strokes in women: ≤5 h: |
|                   |                    |                                     | aHR 0.68 (0.40–1.18), 6 h: aHR 1.25 (0.91–1.70), 7 to 8 h: aHR 1.00,   |
|                   |                    |                                     | 9 h: aHR 1.09 (0.76–1.57), ≥10 h: aHR 0.91 (0.55–1.51). Poor sleep     |
|                   |                    |                                     | quality (difficulty staying asleep) and stroke in men: aHR 1.06 (0.87–1.30). |
|                   |                    |                                     | Poor sleep quality (difficulty staying asleep) and stroke in women:    |
|                   |                    |                                     | aHR 0.87 (0.68–1.10).                                                   |
| Heslop, 2002      | 25 y               | All-cause mortality: 1062/7028      | Sleep duration and all-cause mortality in men: <7 h: aHR 1.15 (0.93–1.42), |
|                   |                    | CVD mortality: 557/7028             | 7 to 8 h: aHR 1.00, >8 h: aHR 0.91 (0.57–1.46). Sleep duration and all-cause mortality in women: <7 h: aHR 1.73 (0.99–3.03), 7 to 8 h: 1.00, >8 h: aHR 0.58 (0.08–4.22). |
|                   |                    |                                     | Sleep duration and CVD mortality in men: <7 h: aHR 1.19 (0.90–1.58),  |
|                   |                    |                                     | 7 to 8 h: aHR 1.0, >8 h: aHR 0.63 (0.30–1.34). Sleep duration and CVD mortality in women: <7 h: aHR 2.30 (0.94–5.60), 7 to 8 h: aHR 1, >8 h: aHR 1.53 (0.20–11.8). |
| Hoevenaar-Blom,   | 11.9 y             | CVD events: 1486/20 432. CHD: 1148/  | Sleep duration on incident CVD: ≤6 h: aHR 1.11 (0.97–1.27), 7 h: aHR   |
| 2011              |                    | 20 432                              | 1.00, 8 h: aHR 0.95 (0.84–1.08), ≥9 h: aHR 0.96 (0.77–1.18). Sleep     |
|                   |                    |                                     | duration and incident CHD: ≤6 h: aHR 1.19 (1.00–1.40), 7 h: aHR 1.00, |
|                   |                    |                                     | 8 h: aHR 0.85 (0.73–1.00), ≥9 h: aHR 0.78 (0.58–1.04). Poor sleep     |
|                   |                    |                                     | quality and incident CVD: aHR 1.04 (0.87–1.26). Poor sleep quality     |
|                   |                    |                                     | and incident CHD: aHR 1.19 (0.96–1.50).                                  |
| Huang, 2013       | 10 y               | All-cause mortality: 182/1865       | Poor sleep quality (good vs poor) and all-cause mortality in men: aHR    |
|                   |                    |                                     | 0.60 (0.42–0.87). Poor sleep quality (good vs poor) and all-cause     |
|                   |                    |                                     | mortality in women: aHR 0.99 (0.68–1.45).                               |
| Hublin, 2007      | 22 y               | All-cause mortality: 3700/21 268    | Sleep duration and all-cause mortality in men: <7 h: aHR 1.26 (1.11–1.43), |
|                   |                    |                                     | 7 to 8 h: aHR 1.00, >8 h: aHR 1.24 (1.09–1.41). Sleep duration and all-cause mortality in women: <7 h: aHR 1.21 (1.05–1.40), 7 to 8 h: aHR 1.00, >8 h: aHR 1.17 |
|                   |                    |                                     | (1.03–1.34). Poor sleep quality and all-cause mortality in men: aHR 1.10 |
|                   |                    |                                     | (0.87–1.39). Poor sleep quality and all-cause mortality in women: aHR 0.99 (0.77–1.27). |
| Ikehara, 2009     | Median 14.3 y      | All-cause mortality: 14 540/98 634.  | Sleep duration and all-cause mortality in men: ≤4 h: aHR 1.29 (1.02–1.64), |
|                   |                    | CVD mortality 4287/98 634. Stroke   | 5 h: aHR 1.02 (0.90–1.16), 6 h: aHR 1.08 (1.00–1.16), 7 h: aHR 1.00,  |
|                   |                    | mortality: 1964/98 634. CHD mortality | 8 h: aHR 1.06 (1.00–1.12), 9 h: aHR 1.13 (1.05–1.22), ≥10 h: aHR 1.41 (1.29–1.54). |
|                   |                    | 881/98 634.                        | Sleep duration and all-cause mortality in women: ≤4 h: aHR 1.28 (1.03–1.60), 5 h: aHR 1.11 (0.98–1.25), 6 h: aHR 1.05 (0.97–1.14), 7 h: aHR 1.00, 8 h: aHR 1.16 (1.08–1.24), 9 h: aHR 1.32 (1.20–1.45), ≥10 h: aHR 1.56 (1.40–1.75). |
|                   |                    |                                     | Sleep duration and CVD mortality in men: ≤4 h: aHR 1.11 (0.67–1.83), 5 h: aHR 0.99 (0.77–1.27), 6 h: aHR 1.01 (0.87–1.18), 7 h: aHR 1.00, 8 h: aHR 1.11 (1.00–1.24), 9 h: aHR 1.14 (0.99–1.32), ≥10 h: aHR 1.56 (1.33–1.83). |

Continued
### Table 2. Continued

| Study ID | Follow-up Duration | Outcomes and Crude Rate of Outcomes | Results |
|----------|--------------------|------------------------------------|---------|
| Jung, 2013<sup>48</sup> | Up to 19 y | All-cause mortality: 1224/2001 | Sleep duration and CVD mortality in women: ≤4 h: aHR 1.28 (0.88–1.86), 5 h: aHR 1.22 (1.00–1.50), 6 h: aHR 1.00 (0.86–1.16), 7 h: aHR 1.00, 8 h: aHR 1.28 (1.14–1.44), 9 h: aHR 1.37 (1.17–1.62), >10 h: aHR 1.54 (1.28–1.86). Sleep duration and stroke mortality in men: ≤4 h: aHR 1.56 (0.82–2.94), 5 h: aHR 0.85 (0.58–1.26), 6 h: aHR 0.95 (0.76–1.20), 7 h: aHR 1.00, 8 h: aHR 1.11 (0.95–1.30), 9 h: aHR 1.14 (0.92–1.42), >10 h: aHR 1.66 (1.31–2.08). Sleep duration and stroke mortality in women: ≤4 h: aHR 1.07 (0.59–1.91), 5 h: aHR 0.99 (0.72–1.37), 6 h: aHR 0.93 (0.75–1.16), 7 h: aHR 1.00, 8 h: aHR 1.24 (1.05–1.47), 9 h: aHR 1.29 (1.01–1.64), >10 h: aHR 1.69 (1.29–2.20). Sleep duration and CHD mortality in men: ≤4 h: aHR 0.29 (0.04–2.05), 5 h: aHR 1.02 (0.62–1.70), 6 h: aHR 0.86 (0.63–1.19), 7 h: aHR 1.00, 8 h: aHR 1.02 (0.82–1.27), 9 h: aHR 0.96 (0.70–1.31), >10 h: aHR 1.12 (0.77–1.63). Sleep duration and CHD mortality in women: ≤4 h: aHR 2.32 (1.19–4.50), 5 h: aHR 1.64 (1.07–2.53), 6 h: aHR 1.23 (0.88–1.72), 7 h: aHR 1.00, 8 h: aHR 1.24 (0.94–1.64), 9 h: aHR 1.52 (1.05–2.19), >10 h: aHR 1.04 (0.83–1.72). |
| Kakizaki, 2013<sup>49</sup> | 13 y | All-cause mortality: 8447/49 256. CVD mortality 2549/49 256. Stroke mortality 1165/49 256. IHD mortality 561/49 256 | Night-time sleep duration and all-cause mortality in men: <6 h: aHR 0.98 (0.673–1.43), 6.0–6.9 h: aHR 1.12 (0.85–1.48) 7.0–7.9 h: aHR 1.0, 8.0–8.9 h: aHR 0.98 (0.79–1.22), ≥9 h: aHR 1.09 (0.82–1.45). Night-time sleep duration and all-cause mortality in women: <6 h: aHR 1.11 (0.77–1.60), 6.0–6.9 h: aHR 1.17 (0.85–1.61) 7.0–7.9 h: aHR 1.0, 8.0–8.9 h: aHR 1.19 (0.90–1.57), ≥9 h: aHR 1.51 (1.05–2.18). |
| Kawachi 2016<sup>50</sup> | Up to 16 y | Stroke mortality: 611/27 896 | Sleep duration and all-cause mortality: ≤6 h: aHR 1.01 (0.93–1.09), 7 h: aHR 1.00, 8 h: aHR 1.07 (1.01–1.14), 9 h: aHR 1.14 (1.06–1.24), >10 h: aHR 1.37 (1.27–1.47). Sleep duration on CVD mortality: ≤6 h: aHR 1.10 (0.96–1.28), 7 h: aHR 1.00, 8 h: aHR 1.21 (1.08–1.36), 9 h: aHR 1.32 (1.15–1.52), ≥10 h: aHR 1.49 (1.30–1.71). Sleep duration and stroke mortality: ≤6 h: aHR 1.05 (0.84–1.30), 7 h: aHR 1.00, 8 h: aHR 1.17 (0.99–1.39), 9 h: aHR 1.30 (1.06–1.60), >10 h: aHR 1.51 (1.24–1.85). Sleep duration and IHD mortality: ≤6 h: aHR 1.38 (1.02–1.86), 7 h: aHR 1.00, 8 h: aHR 1.36 (1.06–1.73), 9 h: aHR 1.49 (1.10–2.02), ≥10 h: aHR 1.41 (1.04–1.92). |
| Kim, 2013<sup>51</sup> | 13 y | All-cause mortality: 19 335/135 885. CVD mortality 6610/135 885. Stroke mortality 1259/135 885. MI mortality: 1188/135 885 | Sleep duration and all-cause mortality in men: aHR ≤5 h: 1.15 (1.06–1.23), 6 h: aHR 1.04 (0.99–1.10), 7 h: aHR 1.00, 8 h: aHR 1.13 (0.91–1.40), ≥9 h: aHR 1.51 (1.16–1.97). Sleep duration and stroke mortality in men: ≤6 h: aHR 0.51 (0.34–0.77), 7 h: aHR 1.00, 8 h: aHR 0.88 (0.66–1.17), ≥9 h: aHR 1.23 (0.90–1.69). Sleep duration and stroke mortality in women: ≤5 h: aHR 1.06 (0.75–1.50), 7 h: aHR 1.00, 8 h: aHR 1.50 (1.10–2.04), ≥9 h: aHR 1.93 (1.38–2.70). |

Continued
Table 2. Continued

| Study ID | Follow-up Duration | Outcomes and Crude Rate of Outcomes | Results |
|----------|-------------------|------------------------------------|---------|
| **Sleep duration and CVD mortality in women:** | | aHR ≤5 h: 1.20 (1.05–1.36), 6 h: aHR 1.06 (0.96–1.18), 7 h: aHR 1.00, 8 h: 1.08 (0.98–1.20), ≥9 h: 1.29 (1.13–1.47). | |
| | | aHR ≤5 h: 1.02 (0.74–1.40), 6 h: aHR 1.10 (0.88–1.37), 7 h: aHR 1.00, 8 h: 1.13 (0.91–1.39), ≥9 h: 1.35 (1.03–1.75). | |
| **Sleep duration and stroke mortality in women:** | | aHR ≤5 h: 1.16 (0.88–1.52), 6 h: aHR 0.99 (0.79–1.23), 7 h: aHR 1.00, 8 h: 1.07 (0.87–1.33), ≥9 h: 1.39 (1.06–1.83). | |
| Kojima, 2000 | 12 y | All-cause mortality: 256/5322 | |
| Kripke, 2002 | Up for 6 y | All-cause mortality: 77 640/1 116 936 | |
| Lan, 2007 | 8 y | All-cause mortality: 1338/3079. CVD mortality: 379/3079 | |
| Lee, 2014 | 61.7 months | All-cause mortality: 297/3427 | |
| Lee, 2017 | 4.7 y. | All-cause mortality: 72/937. | |

Continued
among 73,702 participants from 10 studies, and the pooled results suggest that poor subjective quality of sleep was not associated with significant increase in mortality (risk ratio, 1.03; 95% confidence interval, 0.93–1.14). Poor sleep quality was associated with a significant and moderate increase in coronary heart disease (risk ratio, 1.44; 95% confidence interval, 1.09–1.85) but not for any other outcomes. The funnel plot for sleep quality did not suggest publication bias.

### Sensitivity Analysis Excluding Studies That Did Not Exclude Baseline CVD, Adjust for Cardiac Risk Factors, and Adjusted for Snoring or Obstructive Sleep Apnea

Sensitivity analysis was performed on the meta-analysis data (Data S18). After exclusion of studies that included participants with baseline CVD, there was a significant increase in all-cause mortality with longer and shorter self-reported hours of sleep (small for 6 hours, modest for 5 and 9 hours, and moderate for 4 and 10 hours) and moderate increase in CVD mortality and stroke mortality with longer hours of sleep. Similar observations were found for studies that adjusted for CVR factors. For the analysis of CHD and stroke, there were significant and moderate increases in events when baseline CVD was excluded with 5-hour duration of sleep. For the adjustments for obstructive sleep apnea analysis, some of the results were no longer statistically significant because there were fewer studies.

### Discussion

In this meta-analysis of 60 studies representing over 3 million participants, we observed that divergence from the recommended 7 to 8 hours of sleep was significantly associated with a moderate increase in mortality and incident CVD. We observed a J-shaped relationship between sleep duration and mortality, and incident adverse cardiovascular events were observed. When spline analysis was applied to evaluate the incremental association of sleep duration and adverse events, our results suggest that longer than the recommended duration of 7 to 8 hours of sleep may be associated with a moderate degree of harm, compared with those who slept for durations shorter than that recommended.

Our study provides evidence that may contribute to important clinical and public health messages. First, we observed through spline analysis a more-precise estimation of the risk gradient of CVD and mortality on the greater side of the recommended 7 to 8 hours of sleep compared to existing studies. Second, deviations in sleep duration and quality may be a nonspecific marker for increased CVR that might warrant determination of CVR. In particular, clinicians may need to be aware that the risk gradient appears to be
Table 3. Study Cohort, Follow-up and Results for Studies With Authors Magee to Zuuier

| Study ID       | Follow-up Duration | Outcomes and Crude Rate of Outcomes | Results                                                                                     |
|----------------|--------------------|-------------------------------------|--------------------------------------------------------------------------------------------|
| Magee, 2011   | Unclear            | Stroke 6541/218 155. Heart disease 25 669/218 155 | Sleep duration and stroke: <6 h: aOR 1.54 (1.36–1.75), 6 h: aOR 1.25 (1.14–1.38), 7 h: aOR 1.00, 8 h: aOR 1.08 (1.01–1.17), ≥9 h: aOR 1.50 (1.38–1.62). Sleep duration and heart disease: <6 h: aOR 1.23 (1.15–1.33), 6 h: aOR 1.11 (1.06–1.17), 7 h: aOR 1.00, 8 h: aOR 1.01 (0.97–1.05), ≥9 h: aOR 1.14 (1.09–1.19). |
| Magee, 2013   | 2.8 y              | All-cause mortality 8782/227 815    | Sleep duration and all-cause mortality: <6 h: aHR 1.13 (1.01–1.25), 6 h: aHR 0.99 (0.91–1.06), 7 h: aHR 1.00, 8 h: aHR 1.02 (0.96–1.08), 9 h: aHR 1.04 (0.96–1.12), ≥10 h: aHR 1.26 (1.16–1.36). |
| Mellon, 2002  | 12 y               | All-cause mortality 266/2663. Coronary artery disease mortality: 91/2663. | Sleep duration and all-cause mortality in men: <6 h: aRR 1.1 (0.6–7.0), 7 to 8 h: aRR 1.00, >8 h: aRR 2.0 (1.2–3.2). Sleep duration and all-cause mortality in women: <6 h: aRR 1.0 (0.6–1.8), 7 to 8 h: aRR 1.00, >8 h: aRR 1.3 (0.6–2.6). Sleep duration and coronary artery disease mortality in men: <6 h: aRR 0.7 (0.3–1.7), 7 to 8 h: aRR 1.00, >8 h: aRR 2.2 (1.0–4.4). Sleep duration and coronary artery disease mortality in women: <6 h: aRR 1.2 (0.4–4.2), 7 to 8 h: aRR 1.00, >8 h: aRR 0.7 (0.1–5.2). Poor sleep quality (difficulty maintaining sleep) and all-cause mortality in men: aRR 1.4 (1.1–1.9). Poor sleep quality (difficulty maintaining sleep) and coronary artery disease mortality in men: aRR 1.2 (0.7–1.9). Poor sleep quality (difficulty maintaining sleep) and all-cause mortality in women: aRR 1.1 (0.7–1.7). Poor sleep quality (difficulty maintaining sleep) and coronary artery disease mortality in women: aRR 1.1 (0.5–2.9). |
| Martin, 2011  | 1 y                | All-cause mortality: 57/245         | Sleep quality (high PQSI 7-day score) and all-cause mortality: aHR 1.12 (1.04–1.21). |
| Meisinger, 2007 | Unclear            | Acute coronary event: 295/6896     | Sleep duration and acute coronary event in men: ≤5 h: aHR 1.13 (0.66–1.92), 6 h: aHR 1.05 (0.71–1.55), 7 h: aHR 1.22 (0.92–1.61), 8 h: aHR 1.00 (reference), ≥9 h: aHR 1.07 (0.75–1.53). Sleep duration and acute coronary event in women: ≤5 h: aHR 2.98 (1.48–6.03), 6 h: aHR 1.05 (0.49–2.27), 7 h: aHR 1.34 (0.75–2.40), 8 h: aHR 1.00 (reference), ≥9 h: aHR 1.40 (0.74–2.64). Poor sleep quality (difficulty maintaining sleep) and acute coronary events in men: aHR 1.12 (0.84–1.48). Poor sleep quality (difficulty maintaining sleep) and acute coronary events in women: aHR 1.53 (0.99–2.37). |
| Mesas, 2010   | 6.8 y              | All-cause mortality: 897/3820       | Sleep duration and all-cause mortality: <5 h: aOR 1.42 (1.04–1.96), 6 h: aOR 1.23 (0.90–1.69), 7 h: aOR 1.00, 8 h: aOR 1.34 (1.02–1.76), 9 h: aOR 1.48 (1.12–1.96), 10 h: aOR 1.73 (1.30–2.29), ≥11 h: aOR 1.66 (1.23–2.24). |
| Pan, 2014     | Up to 8 y          | Stroke mortality: 1381/63 257       | Sleep duration and stroke deaths: <5 h: aHR 1.25 (1.05–1.50), 6 h: aHR 1.01 (0.87–1.18), 7 h: aHR 1.00, 8 h: aHR 1.09 (0.95–1.26), ≥9 h: aHR 1.54 (1.28–1.85). Sleep duration and ischaemic or unspecified stroke deaths: <5 h: aHR 1.37 (1.12–1.68), 6 h: aHR 1.04 (0.87–1.24), 7 h: aHR 1.00, 8 h: aHR 1.14 (0.96–1.34), ≥9 h: aHR 1.68 (1.36–2.06). Sleep duration and hemorrhagic stroke death: <5 h: aHR 0.92 (0.62–1.36), 6 h: aHR 0.91 (0.67–1.24), 7 h: aHR 1.00, 8 h: aHR 0.97 (0.73–1.29), ≥9 h: aHR 1.14 (0.76–1.72). |
| Patel 2004    | 14 y               | All-cause mortality: 5409/82 969. CVD mortality: 1084/82 969 | Sleep duration and all-cause mortality: <5 h: aRR 1.08 (0.96–1.22), 6 h: aRR 0.99 (0.92–1.06), 7 h: aRR 1.00, 8 h: aRR 1.11 (1.03–1.19), ≥9 h: aRR 1.40 (1.25–1.55). Sleep duration and cardiovascular mortality: <5 h: aRR 1.04 (0.79–1.35), 6 h: aRR |

Continued
Table 3. Continued

| Study ID          | Follow-up Duration | Outcomes and Crude Rate of Outcomes                         | Results                                                                 |
|-------------------|--------------------|-------------------------------------------------------------|------------------------------------------------------------------------|
| Pollak, 199067    | 3.5 y              | All-cause mortality: 309/1855                               | Incremental increase in h of sleep and all-cause mortality in men: HR 0.96 (0.66–1.39). Incremental increase in h of sleep and all-cause mortality in women: HR 1.11 (0.80–1.54). |
| Qiu, 201168       | 3 y                | All-cause mortality: 5199/12 671                            | Sleep duration and all-cause mortality: <5 h: aHR 0.97 (0.88–1.08), 6 h: aHR 1.05 (0.95–1.16), 7 h: aHR 1.00 (0.90–1.11), 9 h: aHR 0.95 (0.83–1.07), >10 h: aHR 1.09 (1.00–1.18). Sleep duration and all-cause mortality and men: <5 h: aHR 1.17 (1.01–1.38), 6 h: aHR 1.06 (0.91–1.25), 7 h: aHR 1.17 (0.99–1.37), 9 h: aHR 1.08 (0.89–1.31), >10 h: aHR 1.22 (1.08–1.38). Sleep duration and all-cause mortality and women: <5 h: aHR 0.85 (0.75–0.98), 6 h: aHR 1.02 (0.90–1.15), 7 h: aHR 0.88 (0.76–1.01), 9 h: aHR 0.86 (0.72–1.02), >10 h: aHR 1.00 (0.90–1.11). Sleep quality (poor vs good) and all-cause mortality: aHR 0.91 (0.83–1.00). Sleep quality (poor vs good) and all-cause mortality in men: aHR 1.11 (0.95–1.30). Sleep quality (poor vs good) and all-cause mortality in women: aHR 0.81 (0.71–0.91). |
| Qureshi, 199769    | 10 y               | Stroke 322/7844. CHD: 474/7844                             | Sleep duration and risk for stroke: <6 h: aOR 1.0 (0.7–1.5), 6 to 8 h: aOR 1.0, >8 h: aOR 1.5 (1.1–2.0). Sleep duration and CHD: <6 h: aOR 1.3 (1.0–1.8), 6 to 8 h: aOR 1.0, >8 h: aOR 1.1 (0.8–1.5). |
| Rhee, 201270      | Up to 15 y         | All-cause mortality: 990/14 533                             | Sleep duration and all-cause mortality: <5 h: aHR 1.53 (1.11–2.12), 6 to 7 h: aHR 1.04 (0.88–1.22), >8 h: aHR 1.00. |
| Rod, 201471       | 22 y.              | All-cause mortality: 804/9098. CVD mortality: 221/9098      | Sleep duration and all-cause mortality in men: ≤5 h: aHR 1.11 (0.73–1.68), 6 h: aHR 1.23 (1.01–1.50), 7 h: aHR 1.00, 8 h: aHR 1.18 (0.92–1.50), >9 h: aHR 1.44 (0.59–3.50). Sleep duration and all-cause mortality in women: ≤5 h: aHR 1.21 (0.76–1.91), 6 h: aHR 1.14 (0.86–1.52), 7 h: aHR 1.00, 8 h: aHR 0.91 (0.63–1.30), >9 h: aHR 1.48 (0.60–3.65). Sleep duration and CVD mortality: ≤6 h: aHR 1.18 (0.87–1.63), 7 to 8 h: aHR 1.00, >9 h: aHR 1.61 (0.40–6.59). Poor sleep quality (disturbed sleep) and all-cause mortality in men: aHR 0.85 (0.62–1.16). Poor sleep quality (disturbed sleep) and all-cause mortality in women: aHR 1.03 (0.70–1.52). Poor sleep quality (disturbed sleep) and CVD mortality: aHR 1.04 (0.72–1.49). |
| Ruigomez, 199572   | 55.7 months        | All-cause mortality 224/1219                               | Sleep duration and all-cause mortality: ≤7 h: aHR 0.83 (0.56–1.23), 7 to 9 h: aHR 1.00, >9 h: aHR 1.37 (0.89–2.11). Sleep duration and all-cause mortality in men: ≤7 h: aHR 1.06 (0.61–1.83), 7 to 9 h: aHR 1.00, >9 h: aHR 1.30 (0.71–2.38). Sleep duration and all-cause mortality in women: ≤7 h: aHR 0.66 (0.37–1.16), 7 to 9 h: aHR 1.00, >9 h: aHR 1.46 (0.79–2.70). |
| Ruiter Petrov, 201473 | 2 y              | Stroke (at least 1 symptom): 224/5666                      | Sleep duration on stroke symptoms: ≤6 h: aHR 1.47 (0.89–2.45), 6 h: aHR 1.22 (0.82–1.81), 7 h: aHR 1.00, 8 h: aHR 1.30 (0.92–1.83), >9 h: aHR 1.42 (0.82–2.45). |
| Sands-Lincoln, 201374 | 10.3 y         | CVD events: 7257/86 329                                   | Sleep duration and CVD: ≤5 h: aHR 1.06 (0.96–1.16), 6 h: aHR 1.00 (0.95–1.06), 7 to 8 h: aHR 1.00, 9 h: aHR 0.95 (0.83–1.08), ≥10 h: aHR 1.23 (0.89–1.70). |

Continued
Table 3. Continued

| Study ID          | Follow-Up Duration | Outcomes and Crude Rate of Outcomes | Results                                                                 |
|-------------------|--------------------|------------------------------------|-------------------------------------------------------------------------|
| Shankar, 2008⁷⁵   | 13 y               | CHD mortality: 1416/58 044          | Sleep duration and CHD: ≤5 h: aHR 1.08 (0.96–1.20), 6 h: aHR 1.00 (0.94–1.07), 7 to 8 h: aHR 1.00, 9 h: aHR 0.93 (0.80–1.08), ≥10 h: aHR 1.33 (0.94–1.88). |
|                   |                    |                                    |                                                                         |
| Song, 2016⁷⁶      | 7.9 y              | Stroke: 3135/95 023                 | Sleep duration and stroke: ≤6 h: aHR 0.92 (0.81–1.05), 6 to 8 h: aHR 1.00, ≥8 h: aHR 1.29 (1.01–1.64).  
Sleep duration and stroke in men: ≤6 h: aHR 0.90 (0.78–1.03), 6 to 8 h: aHR 1.00, ≥8 h: aHR 1.24 (0.96–1.60).  
Sleep duration and stroke in women: ≤6 h: aHR 0.97 (1.0.75–1.60), 6 to 8 h: aHR 1.00, ≥8 h: aHR 1.91 (0.98–3.74). |
|                   |                    |                                    |                                                                         |
| Stone, 2009⁷⁷     | Up to 4.1 y        | All-cause mortality: 793/6107       | Sleep duration and all-cause mortality in men: ≤5 h: RH 1.2 (0.8–1.8), 7 to 8 h: RH 1.00.  
Sleep duration and all-cause mortality in women: ≤5 h: RH 1.8 (1.3–2.5), 7 to 8 h: RH 1.00. |
|                   |                    |                                    |                                                                         |
| Strand, 2016⁷⁸    | 9.7 y              | CHD mortality: 711/392 164          | Sleep duration and CHD mortality: ≤4 h: aHR 1.36 (0.88–2.10), 4 to 6 h: aHR 1.03 (0.85–1.24), 6 to 8 h: aHR 1.00, ≥8 h: aHR 1.28 (1.05–1.56).  
Sleep duration and CHD mortality in men: ≤4 h: aHR 1.03 (0.53–2.00), 4 to 6 h: aHR 1.06 (0.85–1.32), 6 to 8 h: aHR 1.00, ≥8 h: aHR 1.11 (0.88–1.41).  
Sleep duration and CHD mortality in women: ≤4 h: aHR 1.84 (1.03–3.29), 4 to 6 h: aHR 0.99 (0.72–1.57), 6 to 8 h: aHR 1.00, ≥8 h: aHR 1.81 (1.28–2.56).  
Difficulty getting to sleep and CHD mortality: aHR 1.01 (0.80–1.26). |
|                   |                    |                                    |                                                                         |
| Suzuki, 2009¹¹    | 6 y                | All-cause mortality: 1004/14 001.   | Sleep duration and all-cause mortality: ≤5 h: aHR 0.92 (0.66–1.28), 6 h: aHR 1.06 (0.80–1.39), 7 h: aHR 1.41 (1.05–1.90), ≥10 h: aHR 1.96 (1.49–2.57).  
Sleep duration and all-cause mortality in men: ≤5 h: aHR 1.08 (0.72–1.61), 6 h: aHR 1.05 (0.75–1.47), 7 h: aHR 1.00, 8 h: aHR 1.36 (1.04–1.78), 9 h: aHR 1.52 (1.08–2.15), ≥10 h: aHR 1.86 (1.34–2.56).  
Sleep duration and all-cause mortality in women: ≤5 h: aHR 0.71 (0.39–1.29), 6 h: aHR 1.08 (0.67–1.74), 7 h: aHR 1.00, 8 h: aHR 1.39 (0.92–2.09), 9 h: aHR 1.15 (0.64–2.09), ≥10 h: aHR 2.27 (1.37–3.76).  
Sleep duration and CVD mortality: ≤5 h: aHR 1.10 (0.62–1.93), 6 h: aHR 0.85 (0.50–1.45), 7 h: aHR 1.00, 8 h: aHR 1.52 (1.01–2.29), 9 h: aHR 1.55 (0.91–2.63), ≥10 h: aHR 1.95 (1.18–3.21).  
Sleep duration and CVD mortality in men: ≤5 h: aHR 0.97 (0.46–2.05), 6 h: aHR 0.75 (0.38–1.48), 7 h: aHR 1.00, 8 h: aHR 1.05 (0.63–1.75), 9 h: aHR 1.26 (0.65–2.45), ≥10 h: aHR 1.71 (0.94–3.11).  
Sleep duration and CVD mortality in women: ≤5 h: aHR 1.48 (0.59–3.67), 6 h: aHR 1.08 (0.44–2.66), 7 h: aHR 1.00, 8 h: aHR 2.83 (1.39–5.76), 9 h: aHR 2.32 (0.93–5.77), ≥10 h: aHR 2.31 (0.91–5.82).  
Poor sleep quality (frequent awakening) and all-cause mortality: aHR 0.99 (0.83–1.18).  
Poor sleep quality (frequent awakening) and all-cause mortality in men: aHR 1.00 (0.81–1.24).  
Poor sleep quality (frequent awakening) and all-cause mortality in women: aHR 0.96 (0.69–1.31).  
Poor sleep quality (frequent awakening) and CVD mortality: aHR 0.91 (0.66–1.26). |

Continued
Table 3. Continued

| Study ID | Follow-up Duration | Outcomes and Crude Rate of Outcomes | Results |
|----------|--------------------|-------------------------------------|---------|
| Tamakoshi, 2004<sup>79</sup> | 9.9 y | All-cause mortality: 11 071/104 010 | Poor sleep quality (frequent awakening) and CVD mortality in men: aHR 0.89 (0.64–1.28), 5 h: aHR 1.07 (1.01–1.13), 6 h: aHR 1.04 (0.99–1.10), 7 h: aHR 1.02 (0.97–1.07), 8 h: aHR 1.01 (0.96–1.06), ≥9 h: aHR 0.97 (0.89–1.05). Poor sleep quality (difficulty maintaining sleep) and CVD mortality in women: aHR 0.81 (0.49–1.35), 5 h: aHR 1.10 (0.79–1.53), 6 h: aHR 1.13 (0.77–1.67), 7 h: aHR 1.12 (0.76–1.64), 8 h: aHR 1.11 (0.76–1.61), ≥9 h: aHR 1.06 (0.73–1.57). |
| Tsubono 1993<sup>80</sup> | 4 y | All-cause mortality: 207/4318 | Sleep duration and all-cause mortality: ≤6 h: aHR 1.26 (0.81–1.97), 7 to 8 h: aHR 1.00, ≥8 h: aHR 1.58 (1.16–2.15). |
| Tu, 2012<sup>81</sup> | 4 y | Unclear | Sleep duration and MI: ≤6 h: aHR 1.44 (1.26–1.70), 5 h: aHR 0.80 (0.53–1.20), 6 h: aHR 0.82 (0.56–1.19), ≥9 h: aHR 0.89 (0.54–1.49). Sleep duration and strokes: ≤6 h: aHR 2.06 (1.18–3.59), 6 h: aHR 1.13 (0.72–1.77), 7 h: aHR 1.00, 8 h: aHR 1.16 (0.77–1.73), ≥9 h: aHR 1.65 (1.00–2.73). |
| Wingard, 1983<sup>86</sup> | 9 y | All-cause mortality: 369/6928 | Sleep duration and all-cause mortality in men: ≤6 h: 52/352, 7 to 8 h: 142/1735, ≥9 h: 15/132. Sleep duration and all-cause mortality in women: ≤6 h: 35/836, 7 to 8 h: 107/1902, ≥9 h: 17/200. |
The clinical recommendations of the American Heart Association, in which sleep behaviors should be addressed to promote cardiac health, and public health campaigns addressing sleep behavior should include explicit guidelines for adequate sleep.

Our meta-analysis results show a possible increase in mortality with both long and short duration of sleep relative to 7 or 8 hours, but after spline analysis, there is no difference in mortality for patients with shorter sleep duration. The spline regression is the gold standard for metaregression for nonlinear relationships to model exposures and outcomes. We further used this method to perform analysis on the subgroups studies that had more-complete reporting that include crude event rates.

The exact mechanisms that underlie the association between sleep and CVD and mortality are not fully understood. Short sleep duration has been shown to increase levels of leptin and ghrelin, which leads to increased appetite, caloric intake, reduce energy expenditure, and facilitates the development of obesity and impaired glycemic control. Cortisol also increases with reduced sleep, and altered growth hormone metabolism may increase CVR. Low-grade inflammation occurs with reduced sleep, which may be associated with CVD and cancer. Long sleep duration may be associated with an increased risk of CVD because of an adverse CVR factor profile or prevalent comorbidities that lead to fatigue, such as chronic inflammatory disorders and anemia. Depressive symptoms, low socioeconomic status, unemployment, and low physical activity are also associated with long sleep duration, which may confound the association of long sleep with morbidity and mortality.

**Table 3.** Continued

| Study ID      | Follow-up Duration | Outcomes and Crude Rate of Outcomes | Results                                                                 |
|--------------|--------------------|------------------------------------|------------------------------------------------------------------------|
| Xiao, 2014   | 14 y               | All-cause mortality: 44 100/239 896 CVD mortality: 11 635/239 896 | Sleep duration and all-cause mortality: <5 h: aRR 1.16 (1.11–1.26), 5 to 6 h: aRR 1.04 (1.02–1.06), 7 to 8 h: aRR 1.00, ≥9 h: aRR 1.11 (1.06–1.19). Sleep duration and CVD mortality: <5 h: aRR 1.25 (1.13–1.38), 5 to 6 h: aRR 1.06 (1.02–1.10), 7 to 8 h: aRR 1.00, ≥9 h: aRR 1.07 (0.97–1.17). |
| Yeo, 2013    | 9 y                | All-cause mortality: 1580/13 164 CVD mortality: 363/13 164 | Sleep duration and all-cause mortality: <5 h: aHR 1.21 (1.03–1.41), 6 h: aHR 1.10 (0.95–1.27), 7 h: aHR 1.00, 8 h: aHR 1.03 (0.89–1.19), 9 h: aHR 1.36 (1.11–1.67), ≥10 h: aHR 1.36 (1.07–1.72). Sleep duration on CVD mortality: ≤5 h: aHR 1.40 (1.02–1.93), 6 h: aHR 1.25 (0.92–1.69), 7 h: aHR 1.00, 8 h: aHR 1.04 (0.76–1.42), 9 h: aHR 1.26 (0.81–1.96), ≥10 h: aHR 1.37 (0.82–2.29). |
| Zawisza, 2015 | 10.8 y             | All-cause mortality 2093/2449. | Incremental increase in h of sleep and all-cause mortality: aHR 1.04 (1.003–1.075). |
| Zubier, 2015  | 7.3 y              | All-cause mortality: 154/1734.     | Sleep duration and all-cause mortality: ≤6 h: aHR 1.20 (0.77–1.65), 6 to 7.5 h: aHR 1.00, ≥7.5 h: aHR 1.18 (0.70–1.98). |

aHR indicates adjusted hazard ratio; aOR, adjusted odds ratio; aRR, adjusted risk ratio; CHD, coronary heart disease; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction; PSQI, Pittsburgh Sleep Quality Index; RH, relative hazard.
An important consideration in the temporal relationship between sleep and adverse outcomes is the potential influence of CVR factors. For example, a Japanese study observed that sleep disturbances were associated with a higher risk of later-onset of type 2 diabetes mellitus. In addition, it is unclear whether abnormal sleep is a marker of...
undiagnosed prevalent CVDs or of early/latent disease that subsequently manifests in adverse cardiovascular outcomes and death. Some studies have attempted to reduce the effect of baseline prevalent CVD by excluding patients with these conditions whereas other studies adjusted for these factors. Despite our sensitivity analysis considering exclusion.

Figure 3. Linear models for adverse cardiovascular events. A, CHD mortality (8 studies). B, CHD (14 studies). C, Stroke mortality (4 studies). D, Stroke (15 studies). E, CVD mortality (11 studies). F, CVD (8 studies). CHD indicates coronary heart disease; CVD, cardiovascular disease.
and adjustments, there may still be residual confounding given that there may be undiagnosed or latent disease or risk factors because some of these population-based studies do investigate patients at baseline for these variables and rely on self-reporting. The other important consideration is whether the increased incident CVR is causally related to sleep directly or whether abnormal sleep patterns may contribute to adverse health behaviors that increase CVR thereby contributing to the increase in cardiovascular events.

Several studies have evaluated the mismatch between self-reported sleep and more-objective measures. An analysis of 669 participants in the CARDIA (Coronary Artery Risk Development in Young Adults) Sleep Study suggests a moderate correlation between self-reported and objectively measured sleep duration with evidence of systematic errors in the mean and calibration. Another study of 2086 Hispanic Americans suggests a moderate correlation between self-reported sleep and actigraphy results. A smaller study that compared self-reported sleep and actigraphy in 56 participants reported a poor agreement between sleep duration and quality, as assessed by a questionnaire and objectively measured sleep. In addition, a different analysis of 63 patients who were overweight and obese individuals and who underwent actigraphy also reported a weak correlation between usual sleep time and actigraph estimates. With respect to CVR, studies suggest that self-reported sleep duration is different from objectively assess sleep duration. Although the exact reasons for discrepancies between subjective and objective measures are not clear, it appears that self-reported sleep is only, at best, moderately correlated with objective measures of sleep and perhaps multiple measures of sleep duration should be recommended for future studies.

In the current analysis, the study by Kripke et al represented more than one third of the entire cohort, and this large study has implications to the interpretation of the results. This cohort was a diverse group of adults who were friends or relatives of American Cancer Society volunteers who were aged between 30 and 102 years. The mean age in this study was 57 years and 43% of participants were female, which were both slightly lower than the average of 60 years of age and 52% female in all the included studies. In addition, the study took place in the 1980s, which may affect the applicability of its findings to the current population. Collectively, these findings may limit the generalizability of the current study.

Our study has a number of limitations. Although we used adjusted estimates where available, there are likely to be residual or unmeasured confounding and bias. For example, an underlying physical or mental health condition may be the driver behind extreme sleep patterns. A key limitation was that sleep duration was assessed by self-reported questionnaires. It is unclear whether this is truly reflective of actual sleep patterns given that there are studies that clearly show that with respect to CVR, self-reported sleep duration and objectively assessed sleep duration are significantly different. Another limitation was the absence of individual patient-level data, so we could not make assumptions about the CVR factor profiles of patients based on their sleep duration or quality. Some studies did report baseline risk factors for patients, but every study reported different risk factors, and the combinations of the risk-factor profiles reported were too heterogeneous to make general assumptions. Although we demonstrated an association between sleep quality, duration, and outcomes, these relationships cannot infer causality and it is unclear whether sleep duration or quality is a marker of prevalent CVR, an adverse CVR factor profile, or adverse health behaviors that contribute to the adverse outcomes reported.

Conclusion

In conclusion, we found a significant association between deviations in sleep duration and both mortality and adverse cardiovascular outcomes. National guidelines should consider advocating this as the recommended sleep duration. We also found evidence that sleep duration above the recommended level of 7 to 8 hours was associated with a moderate degree of harm compared with sleeping less than the suggested duration. Furthermore, the greater the divergence from the recommended durations of sleep, the greater the association for cardiovascular harm and mortality. Our study suggests that abnormal sleep is a marker of elevated CVR—and greater consideration should be given in exploring during patient consultations in both the duration and quality of sleep.

Acknowledgments

We thank Francesco Cappuccio for his useful comments and suggestions.

Disclosures

None.

References

1. American Heart Association. 2015 Heart Disease and Stroke Statistics. Available at: https://www.heart.org/idc/groups/ahamah-public/@wcm/@sop/@smd/documents/downloadable/ucm_470704.pdf. Accessed June 27, 2018.
2. Meng L, Zheng Y, Hui R. The relationship of sleep duration and insomnia to risk of hypertension incidence: a meta-analysis of prospective cohort studies. Hypertens Res. 2013;36:985–995.
3. Guo X, Zheng L, Wang J, Zhang X, Zhang X, Li J, Sun Y. Epidemiological evidence for the link between sleep duration and high blood pressure: a systematic review and meta-analysis. Sleep Med. 2013;14:324–332.
4. Holliday EG, Magee CA, Kritsahrides L, Banks E, Atitai J. Short sleep duration is associated with risk of future disease but no cardiovascular disease: a prospective study and meta-analysis. PLoS One. 2013;8:e82305.
5. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. *Diabetes Care*. 2010;33:414–420.

6. Patel SR, Hu FB. Short sleep duration and weight gain: a systematic review. *Obesity*. 2008;16:643–653.

7. Cappuccio FP, Taggart FM, Kandala NB, Currie A, Peile E, Stranges S, Miller MA. Meta-analysis of short sleep duration and obesity in children and adults. *Sleep*. 2008;31:619–626.

8. Westerlund A, Bellocchio R, Sundstrom J, Adami HO, Akerstedt T, Tolle Lagreros Y. Sleep characteristics and cardiovascular events in a large Swedish cohort. *Eur J Epidemiol*. 2013;28:463–473.

9. Leng Y, Cappuccio FP, Wainwright NW, Surtees PG, Luben R, Brayne C, Khaw KT. Sleep duration and risk of fatal and nonfatal stroke: a prospective study and meta-analysis. *Neurology*. 2015;84:1072–1079.

10. Cappuccio FP, Cooper D, D’Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. *Eur Heart J*. 2011;32:1482–1492.

11. Suzuki E, Yorifugi T, Ueshima K, Takao S, Sugiyama M, Ohta T, Ishikawa-Takata K, Doi H. Sleep duration, sleep quality and cardiovascular disease mortality among the elderly: a population-based cohort study. *Prev Med*. 2009;49:135–141.

12. Hoevenaar-Blom MP, Spijkerman AM, Kroghoudt D, van den Berg JF, Verchuren WM. Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: the MORGENT study. *Sleep*. 2011;34:1487–1492.

13. McBeth J, Wilkie R, Bedson J, Chew-Graham CA, Lacey R. Sleep disturbance and incidence of type 2 diabetes: a systematic review and meta-analysis. *Diabetes Care*. 2008;31:1241–1245.

14. National Sleep Foundation. National Sleep Foundation Recommends New Sleep Times. Available at: http://sleepfoundation.org press release national-sleep-foundation-recommends-new-sleep-times/page/01. Accessed June 27, 2018.

15. CDC. Are you getting enough sleep? Available at: http://www.cdc.gov features/sleep/index.html. Accessed June 27, 2018.

16. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. *Sleep*. 2010;33:585–592.

17. McBeth J, Wilkie R, Bedson J, Chew-Graham CA, Lacey R. Sleep disturbance and chronic widespread pain. *Curr Rheumatol Rep*. 2015;17:1–10.

18. Akerstedt T, Nilsson PM. Sleep as restitution: a introduction. *Scand J Work Environ Health*. 2006;32:1003–1009.

19. Ensrud KE, Blackwell TL, Ancoli-Israel S, Redline S, Cawthon PM, Paudel ML, Dam TTM. Sleep disturbances and risk of frailty and mortality in older men. *Sleep Med*. 2012;13:1217–1225.

20. Gangwisch JE, Heymsfeld SB, Boden-Alba B, Guji RM, Kreier F, Opler MG, Pickering TG, Rundle AG, Zammit GK, Malaspina D. Sleep duration associated with mortality in elderly, but not middle-aged, adults in a large US sample. *Sleep*. 2008;31:1087–1096.

21. Garde AH, Hansen AM, Holtermann A, Gyntelberg F, Suadicani P. Sleep duration and ischemic heart disease and all-cause mortality: prospective cohort study on effects of transilluminators/hynotics and perceived stress. *Scand J Work Environ Health*. 2013;39:550–558.

22. Gianfagna F, Veronesi G, Bertu L, Cesana G, Grassi G, Stranges S, Callegari C, Ferrari MM. Influence of sleep disturbances on the adult-onset at age onset and long-term incidence of major cardiovascular events: the MONICA-Briana and PAMELA cohort studies. *Sleep Med*. 2016;21:126–132.

23. Goto A, Yasumara S, Nishide Y, Sakihara S. Association of health behaviour and social roles with total mortality among Japanese elders in Okinawa, Japan. *Aging Clin Exp Res*. 2003;15:643–450.

24. Hale L, Parente V, Dowd JB, Sands M, Berger JS, Song Y, Martin LW, Allison MA. Fibrinogen may mediate the association between long sleep duration and coronary heart disease. *J Sleep Res*. 2013;22:305–314.

25. Hall MHK, Smagula SF, Boudreau RM, Ayonayon HM, Goldman SE, Harris TB, Naydeck BL, Rubin SM, Samuelsson L, Satterfield S, Stone KL, Visser M, Newman AB. Association between sleep duration and mortality is mediated by markers of inflammation and health in older adults: the Health, Aging and Body Composition Study. *Sleep*. 2015;38:189–195.

26. Hamazaki Y, Morikawa Y, Nakamura K, Sakurai M, Miura K, Ishizaki M, Kido T, Naruse Y, Suwazono Y, Nakagawa H. The effects of sleep duration on the incidence of cardiovascular events among middle-aged male workers in Japan. *Scand J Work Environ Health*. 2011;37:411–417.

27. Helbig AK, Stock I, Heier M, Ladwig KH, Meisinger C. Symptoms of insomnia and sleep duration and their association with incident strokes: findings from the population-based MONICA/KORA Augsburg Cohort study. *PLoS One*. 2015;10:e013480.

28. Hesper P, Smith GD, Maelcffe C, Macleod J, Hart C. Sleep duration and mortality: the effect of short or long sleep duration on cardiovascular and all-cause mortality in working men and women. *Sleep Med*. 2002;3:305–314.

29. Huang WC, Wah lounge ML, Lee MS. Sleep quality and survival of elderly Taiwanese for dietary diversity and pyridoxine in men and women. *Am Coll Nutr*. 2013;32:417–427.

30. Hublin C, Partinen M, Koskenvuo M, Kaprio J. Sleep and mortality: a population-based 22-year follow-up study. *Sleep*. 2007;30:1245–1253.

31. Rehara S, Isi H, Date C, Kikuchi S, Watanabe Y, Wada Y, Inaba Y, Tamakoshi A. Association of sleep duration and mortality from cardiovascular disease and other causes for Japanese men and women: the JACC study. *Sleep*. 2009;32:259–301.
Sleep Duration and Quality and CVD and Mortality  Kwok et al

48. Jung KI, Song CH, Ancholi-Israel S, Barrett-Conner E. Gender differences in nighttime sleep and daytime napping in factors of mortality in older adults: the Rancho Bernardo Study. Sleep Med. 2013;14:12–19.

49. Kakizaki M, Kuriyama S, Nakaya N, Sone T, Nagai M, Sugawara Y, Hozawa A, Fukudo S, Tsuji I. Long sleep duration and cause-specific mortality according to physical function and self-rated health: the Ohsaki cohort study. J Sleep Res. 2013;22:209–216.

50. Kawachi T, Wada K, Nakamura K, Tsuji M, Tamura T, Konishi K, Nagata C. Sleep duration and the risk of mortality from stroke in Japan, The Takayama Cohort Study. J Epidemiol. 2016;26:123–130.

51. Kim Y, Wilkens LR, Schembre SM, Henderson BE, Kolonel LN, Goodman MT. Insufficient and excessive amounts of sleep increase the risk of premature death from cardiovascular and other disease: the Multiethnic cohort study. Prev Med. 2013;57:377–385.

52. Kojima M, Wakai K, Kawamura T, Tamakoshi A, Aoki R, Lin Y, Nakayama T, Horibe H, Aoki N, Ohno Y. Sleep, patterns and total mortality: a 12-year follow-up study in Japan. J Epidemiol. 1999;10:87–93.

53. Kripke DF, Garlinkel L, Wingard DL, Hetta J. Sleep complaints predict coronary artery disease in older people independent of frailty: a 5-year cohort study. J Am Med Dir Assoc. 2014;15:649–654.

54. Lee JW, Pen LN, Lian CK, Chiou ST, Chen LK. Long sleep duration, independent of frailty and chronic inflammation, was associated with higher mortality: a national population-based study. Geriatr Gerontol Int. 2017;17:1481–1487.

55. Li Y, Sato Y, Yamaguchi N. Potential biochemical pathways for the relationship between sleep duration and mortality. Sleep Med. 2013;14:98–104.

56. Liu J, Yuen J, Kang S. Sleep duration, C-reactive protein and risk of incident diabetes in Chinese men: the Kailuan study. Sleep Med. 2013;14:591–596.

57. Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Intern Med. 2002;251:207–216.

58. Martin JL, Fiorentino L, Joulidjan S, Mitchell M, Josephson KR, Alessi CA. Poor self-reported sleep quality predicts mortality within one year of inpatients recovering from stroke: the HAMS study. Sleep. 2011;34:1715–1721.

59. Meisenger C, Heier M, Lowel H, Schneider A, Doring A. Sleep duration and sleep complaints and risk of myocardial infarction in middle-aged men and women from the general population: the MONICA/KORA Augsburg Cohort Study. Sleep. 2007;30:1121–1127.

60. Mesas AE, Lopez-Garcia E, Leong Munoz LM, Guallar-Castillon P, Rodriguez-Artalejo F. Sleep duration and mortality according to health status in older adults. Am J Geriatr Soc. 2010;58:1870–1877.

61. Pan A, de Silva DA, Yuan JM, Koh WP. Sleep duration and risk of stroke mortality among Chinese adults. Stroke. 2014;45:1620–1625.

62. Patel SR, Ayas NT, Malhotra MR, White DP, Schernhammer ES, Speizer FE, Stamfer MJ, Hu FB. A prospective study of sleep duration and mortality risk in women. Sleep. 2004;27:440–444.

63. Pollak CP, Perlick D, Linsner JP, Wenston J, Hsieh F. Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health. 1990;15:123–135.

64. Qui L, Sautter J, Liu Y, Gu D. Age and gender differences in linkages of sleep with subsequent mortality and health among very old Chinese. Sleep Med. 2011;1008–1017.

65. Qureshi AI, Giles WH, Croft JB, Bliwise DL. Habitual sleep patterns and risk for stroke and coronary heart disease: a 10-year follow-up from NHANES I. Neurology. 1997;48:904–911.

66. Rhee CW, Kim JY, Park BJ, Li ZM, Ahn YO. Impact of individual and combined health behaviours on all causes of premature mortality among middle aged men in Korea: the Seoul Male Cohort Study. J Prev Med Public Health. 2012;45:14–20.

67. Rod NH, Kumari M, Lange T, Kwimaki M, Shipley M, Ferrie J. The joint effect of sleep duration and disturbed sleep on cause-specific mortality: results from the Whitehall II cohort study. PLoS One. 2014;9:e91965.

68. Ruigomez A, Zbongos J, Anto JM. Relationship of health behaviours to five-year mortality and adverse COPD outcomes. Sleep Med. 2012;13:474–483.

69. Ruiter Petrov ME, Letter AJ, Howard VJ, Kleinodfer D. Self-reported sleep duration in relation to incident stroke symptoms: influence by body mass and race from the REGARDS study. J Stroke Cerebrovasc Dis. 2014;23:e123–e132.

70. Sands-Lincoln M, Loucks EB, Lu B, Carskadon MA, Sharkey K, Stefanick ML, Ockene J, Shah N, Hairston KG, Robinson JG, Limacher M, Hales L, Eaton CB. Sleep duration, insomnia, and coronary heart disease among postmenopausal women in the Women's Health Initiative. J Womens Health. 2013;22:477–486.

71. Shankar A, Koh WP, Yan JM, Lee HP, Yu MC. Sleep duration and coronary heart disease mortality among Chinese adults in Singapore: a population-based cohort study. Am J Epidemiol. 2008;168:1367–1373.

72. Song Q, Liu X, Zhou W, Wang L, Zheng X, Wang X, Wu S. Long sleep duration and risk of ischemic stroke and hemorrhagic stroke: the Kallauan Prospective Study. Sci Rep. 2016;6:33644.
96. Kawakami N, Takatsuka N, Shimizu H. Sleep disturbance and onset of type 2 diabetes. *Diabetes Care.* 2004;27:282–283.

97. Lauderdale DS, Knutson KL, Yan LL, Liu K, Rathouz PJ. Sleep duration: how well do self-reports reflect objective measures? The CARDIA Sleep Study. *Epidemiology.* 2008;19:838–845.

98. Cespedes EM, Hu FB, Redline S, Rosner B, Alcantara C, Cai J, Hall MH, Loredo JS, Mossavar-Rahmani Y, Ramos AR, Reid KJ, Shah NA, Sotres-Alverez D, Zee PC, Wang R, Patel SR. Comparison of self-reported sleep duration with actigraphy: results from Hispanic Community Health Study/Study of Latinos Sueno Ancillary Study. *Am J Epidemiol.* 2016;183:561–565.

99. Girschik J, Fritschi L, Heyworth J, Waters F. Validation of self-reported sleep against actigraphy. *J Epidemiol.* 2012;22:462–468.

100. O’Brien E, Hart C, Wing RR. Discrepancies between self-reported usual sleep duration and objective measures of total sleep time in treatment seeking overweight and obese individuals. *Behav Sleep Med.* 2016;14:539–549.

101. King CR, Knutson KL, Rathouz PJ, Sidney S, Liu K, Lauderdale DS. Short sleep duration and incident coronary artery calcification. *JAMA.* 2008;300:2859–2866.

102. Reinhard W, Plappert N, Zeman F, Hengstenberg C, Riegger G, Novack V, Maimon N, Pfeifer M, Arzt M. Prognostic impact of sleep duration and sleep efficiency on mortality in patients with chronic heart failure. *Sleep Med.* 2013;14:502–509.